Novartis' net income 2007-2024
Novartis AG, one of the world’s top pharmaceutical companies, reported a high net income of nearly 12 billion U.S. dollars in 2024. However, two years before, the net income was even higher, at a record high 24 billion dollars.
Novartis revenue and expenses
Being a Swiss-based company, Novartis generated around one third of its revenue, namely 15.5 billion U.S. dollars, in Europe in 2024. With approximately 21 billion U.S. dollars, the United States was the company's most important market in that year. Novartis AG made 37 billion U.S. dollars from its branded pharmaceuticals ("Promoted brands") segment that year, the company’s largest segment. Novartis spun-off its generic drugs division Sandoz in mid-2023, while eye care division Alcon was spun off in back April 2019. The company spends most of its resources on SG&A (selling, general and administration): expenses for this category reached around 12.6 billion U.S. dollars in 2024. Research and development expenditures amounted to some 10 billion U.S. dollars in the same year.
